GlobeNewswire

Expanding Global Deployments of Product Cost Management Drive New Capabilities in Latest Release

Dela

New Simulation-Driven Design Features in aPriori Professional 2018 R1 Help Improve Product Profitability & Accelerate Time to Market

 

CONCORD, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- aPriori, the leading provider of automated product cost management (PCM) software and service solutions for global manufacturers, today announced the newest release of the company's flagship product, aPriori Professional 2018 R1.

This new release concentrates on helping manufacturers combat some of the most critical challenges they are facing in their businesses today, including:

  • Aerospace manufacturers are struggling with how to accommodate fixed price contracts and maintain profitability in an environment where new materials and manufacturing processes are being introduced continuously.
  • Automotive manufacturers are struggling with major platform redesigns that are required to meet the demand for new electrified and autonomous vehicles.
  • Industrial Machinery manufacturers are faced with new competition from more nimble start-up competitors in low cost countries that continue to put pressure on bringing new innovations to market faster.
  • Electronic & High Tech product manufacturers are facing extreme challenges to bring innovative products to market faster requiring near perfect collaboration with their Contract Manufacturing partners who face their own challenges generating accurate quotes for new product designs in a timely manner.

Highlights of aPriori Professional 2018 R1

With aPriori 2018 R1, the company continues its commitment to helping customers overcome these challenges using time-proven product cost management business strategies and the world's most advanced PCM technology platform.  The primary highlights of this release include:

  • aPriori 2018 R1 has been extended to more easily integrate into engineering automation tools that support a Design of Experiments to simultaneously optimize product designs for performance and cost.
  • Continued advances have been made in the area of Design to Cost / Design for Manufacturability features so that engineering can quickly and easily get cost and manufacturability feedback early in the design process to eliminate late stage rework and product launch delays.
  • aPriori 2018 R1 also features significant upgrades to the Additive Manufacturing cost model, enabling end users to compare traditional subtractive manufacturing processes and additive manufacturing approaches.  Specifically, aPriori now supports Direct Metal Laser Sintering (DMLS) which is often used to make metal parts in aerospace, industrial and medical industries. 
  • With aPriori 2018 R1, a new Stretch Forming cost model is being introduced.  This manufacturing technique is commonly used in aerospace manufacturers to make large multi-curvature parts with low production rates, such as empennage, wing, fuselage and nacelle components on an airplane.
  • aPriori is one of the pioneers responsible for providing quick, automated costing from 3D solid CAD models. In aPriori 2018 R1, aPriori continues its pioneering work in automated design model costing by introducing support for costing of surface models.  Surface models are still used extensively for complex sheet metal parts particularly in the automotive industry.

The items above represent a fraction of the new capabilities delivered in aPriori 2018 R1.  Hundreds of additional enhancements have been implemented in the product's core Sheet Metal, Sand Casting, Plastic Molding and Bar & Tube cost models, many of which were driven through our collaboration with our expanding customer base.  For a complete list of new features available with aPriori 2018 R1, customers can refer to our Release Notes in the HelpCenter.  An aPriori Support system password is required to access this documentation.

Watch a 2 Minute Video of aPriori 2018 R1 DTC/DFM Capabilities

Enhanced Costing Capabilities for Printed Circuit Board Assembly

With this new release, aPriori continues to upgrade its capabilities around costing the assembly of Wire Harnesses and Printed Circuit Boards.  Through a collaborative process with strategic industry partners, aPriori has implemented the following improvements to our electrical/electronics cost models:

  • Performance - costing times are reduced by approximately 50-70% for PCBA and Wire Harness
  • Improved Manufacturing Analysis - aPriori 2018 R1 includes numerous updates throughout both modules to better align with real world manufacturing practices
  • Workflow - this new release provides better control over which components are used from the component library; users now specify which supplier or manufacturer they want to use for each component as well as having direct control over the purchase quantity assumptions

Watch an Overview of Our Enhanced PCBA Solution

"Our growing customer base in aerospace, automotive, industrial machinery, and electronics markets are facing some extreme challenges in bringing their products to market faster and at target cost.  This latest release of aPriori represents another big step forward in our efforts to provide cost and manufacturability guidance for our customers," reported Julie Driscoll, Vice President of Strategic Marketing and Product Management.  "Our PCM technology platform is highly unique in that it supports the entire design to delivery process.  Our company was founded on the principle that each day designers, buyers, cost engineers, manufacturing engineers and department leaders are making tradeoff decisions that have a significant impact on product profitability.  aPriori 2018 R1 continues our commitment to providing cost solutions that allow individuals across the entire product lifecycle to understand the cost impact of these decisions - at the exact moment they are making those decisions."

About aPriori
aPriori software and services generate hard-dollar product cost savings for discrete manufacturing and product innovation companies. Using aPriori's real-time product cost assessments, employees in engineering, sourcing and manufacturing make more-informed decisions that drive costs out of products pre- and post-production. With aPriori, manufacturers launch products at cost targets, maximize savings in re-work projects and avoid overpaying for sourced parts.  To learn more about aPriori and its product cost management solutions and services, visit www.apriori.com or call 1.978.371.2006.

aPriori on Twitter @aPriori_Inc. 
aPriori on XING https://www.xing.com 
Enterprise Product Costing Blog

aPriori and aPriori Technologies are registered trademarks of aPriori Technologies Inc. All other trademarks, registered trademarks or service marks belong to their respective holders.

CONTACT:
Rick Burke
Vice President, Marketing
rburke@apriori.com
978.451.7675



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aPriori Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum